Search clinical trials for: Cetuximab plus FOLFIRI/FOLFOX

Total 279 results

National Cancer Center Hospital East
Japan Agency for Medical Research and Development; Japan Clinical Oncology...

Recruiting

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer (JCOG1801)

Rectal Cancer Recurrent

Japan
GERCOR - Multidisciplinary Oncology Cooperative...

Unknown

Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer

Colorectal Cancer

France
Beijing Anzhen Hospital

Completed

Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography

Randomized Controlled Trials

China
GERCOR - Multidisciplinary Oncology Cooperative...

Active, not recruiting

Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (IDEA)

Colorectal Cancer

France
Asian Institute of Gastroenterology, India

Completed

Pre-medication With N-acetylcysteine and Simethicone to Improve Mucosal Visibility During Gastroduodenoscopy (SIMETHICONE)

Mucosal Erosion

India
Centre Hospitalier Universitaire de Besancon

Recruiting

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02)

Metastatic Colorectal Cancer

France
Guangxi Medical University

Withdrawn

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (LD-FOX4/HCC)

Hepatocellular Carcinoma
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb; National Cancer Institute (NCI); Sanofi; Pfizer; Eastern Cooperative...

Completed

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
Malaria Consortium

Recruiting

Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso (BF-IPTsc)

Malaria

Burkina Faso
Fred Hutchinson Cancer Center

Terminated

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | KSHV-associated Multicentric Castleman Disease

Uganda
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Active, not recruiting

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
NSABP Foundation Inc
Sanofi

Withdrawn

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA

Completed

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Metastatic Colorectal Cancer (mCRC)

Argentina, Brazil, India, Spain, Ukraine
Allergan

Completed

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

Dry Eye Syndrome

United States
University of Luebeck

Completed

Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus

Pemphigus

Germany
AstraZeneca

Completed

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Advanced Solid Tumor

United States
University of California, Irvine
Natera, Inc.

Not yet recruiting

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Gastroesophageal Adenocarcinoma

United States
Yanhong Deng

Recruiting

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (TRIBE-C)

Colorectal Cancer

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Terminated

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage IV HPV-Mediated (p16-Positive)... and other conditions

United States
Georgetown University

Completed

Molecularly Tailored Therapy for Pancreas Cancer

Pancreatic Cancer

United States
Peking University People's Hospital
Beijing Hospital

Unknown

Treatment of ITP With Rituximab and / or Accutane

Immune Thrombocytopenia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin Lymphoma

United States
Gruppo Oncologico del Nord-Ovest

Active, not recruiting

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC)

Metastatic Colorectal Cancer

Italy
Novartis Pharmaceuticals

Active, not recruiting

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Renal Cell Carcinoma | Colorectal Cancer | Gastroesophageal Cancer

United Kingdom, Australia, Belgium, Germany, Italy, Taiwan, Czechia, Israel, Spain, Japan, Singapore, Canada, Korea, Republic of, United States, Chile
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
International Centre for Diarrhoeal Disease Research...
University of California, Davis

Completed

Community-based Follow-up of Severely Malnourished Children

Malnourished Children
Aarhus University Hospital
GCP-unit at Aarhus University Hospital, Aarhus, Denmark

Completed

Alemtuzumab and CHOP in T-cell Lymphoma (ACT-1)

Lymphoma, T-Cell, Peripheral

Norway, Belgium, Finland, Denmark, Austria, Czechia, Portugal, Germany, Netherlands, Poland, Sweden
IGM Biosciences, Inc.

Recruiting

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Sarcoma | Acute Myeloid Leukemia | Colorectal Cancer | Solid Tumor | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chondrosarcoma | Small Lymphocytic Lymphoma

United States, Korea, Republic of, France, Spain, Australia
McMaster University
Icahn School of Medicine at Mount Sinai; Edward-Elmhurst Health System

Completed

Chalazion Conservative Treatment Trial

Chalazion Unspecified Eye, Unspecified Eyelid | Chalazion Left Eye, Unspecified Eyelid | Chalazion Right Eye, Unspecified Eyelid | Chalazion Both Eyes

United States, Canada
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
Organon and Co

Completed

A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)

Osteoporosis, Postmenopausal
Hoffmann-La Roche

Completed

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (MODUL)

Colorectal Cancer

Italy, Korea, Republic of, United Kingdom, Belgium, Argentina, Denmark, Greece, Netherlands, Slovenia, Spain, Sweden, Turkey, Brazil, Bosnia and Herzegovina, France, Germany, Portugal, Egypt, Poland, Slovakia, Mexico, Serbia, Russian...
Hoffmann-La Roche

Terminated

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Neoplasms

United States
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia With BCR-ABL1

United States
Yanhong Deng

Recruiting

Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (FOBEAR)

Rectal Cancer

China
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States
Istanbul Medeniyet University
Abdi Ibrahim Ilac San. ve Tic A.S.

Completed

Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis

Osteoarthritis
Uppsala University

Completed

Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer

Gastric Cancer | Peritoneal Carcinomatosis

Sweden
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | Stage... and other conditions

United States, Canada, Hong Kong
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | CD20 Positive | Lymphocytic Neoplasm

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Treatment-naїve Mantle Cell Lymphoma

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States

Search clinical trials for: Cetuximab plus FOLFIRI/FOLFOX

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations